##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	snp	210	210	.	+	.	ID=ID_0;Name=c.G-56T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G-56T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	241	241	.	+	.	ID=ID_1;Name=c.C-25T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C-25T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	581	581	.	+	.	ID=ID_2;Name=p.V106I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=leader protein;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725297.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A;nt_name=c.G316A;aa_name=p.V106I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	3037	3037	.	+	.	ID=ID_3;Name=p.F924F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.F924F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	4181	4181	.	+	.	ID=ID_4;Name=p.A1306S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G3916T;aa_name=p.A1306S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	4582	4582	.	+	.	ID=ID_5;Name=p.N1439N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C4317T;aa_name=p.N1439N;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	5308	5308	.	+	.	ID=ID_6;Name=p.L1681L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A5043G;aa_name=p.L1681L;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	5570	5570	.	+	.	ID=ID_7;Name=p.M1769V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A5305G;aa_name=p.M1769V;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	5812	5812	.	+	.	ID=ID_8;Name=p.D1849D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C5547T;aa_name=p.D1849D;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	6402	6402	.	+	.	ID=ID_9;Name=p.P2046L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C6137T;aa_name=p.P2046L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	7124	7124	.	+	.	ID=ID_10;Name=p.P2287S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C6859T;aa_name=p.P2287S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	7848	7848	.	+	.	ID=ID_11;Name=p.R2528K;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A;nt_name=c.G7583A;aa_name=p.R2528K;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	8626	8626	.	+	.	ID=ID_12;Name=p.F2787F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C8361T;aa_name=p.F2787F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	8986	8986	.	+	.	ID=ID_13;Name=p.D2907D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C8721T;aa_name=p.D2907D;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	9053	9053	.	+	.	ID=ID_14;Name=p.V2930L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G8788T;aa_name=p.V2930L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	10029	10029	.	+	.	ID=ID_15;Name=p.T3255I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C9764T;aa_name=p.T3255I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	10376	10376	.	+	.	ID=ID_16;Name=p.P3371S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3C-like proteinase;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725301.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C10111T;aa_name=p.P3371S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	11201	11201	.	+	.	ID=ID_17;Name=p.T3646A;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A10936G;aa_name=p.T3646A;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	11332	11332	.	+	.	ID=ID_18;Name=p.V3689V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A11067G;aa_name=p.V3689V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	14408	14408	.	+	.	ID=ID_19;Name=p.P4715L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C14144T;aa_name=p.P4715L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	14708	14708	.	+	.	ID=ID_20;Name=p.A4815V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C14444T;aa_name=p.A4815V;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	14856	14856	.	+	.	ID=ID_21;Name=p.V4864V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A14592G;aa_name=p.V4864V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	14961	14961	.	+	.	ID=ID_22;Name=p.N4899N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=T;Variant_seq=C;nt_name=c.T14697C;aa_name=p.N4899N;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	15451	15451	.	+	.	ID=ID_23;Name=p.G5063S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A;nt_name=c.G15187A;aa_name=p.G5063S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	16466	16466	.	+	.	ID=ID_24;Name=p.P5401L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C16202T;aa_name=p.P5401L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	17304	17304	.	+	.	ID=ID_25;Name=p.V5680V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=G;nt_name=c.C17040G;aa_name=p.V5680V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	18651	18651	.	+	.	ID=ID_26;Name=p.E6129D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3'-to-5' exonuclease;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_acc=YP_009725309.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G18387T;aa_name=p.E6129D;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	19220	19220	.	+	.	ID=ID_27;Name=p.A6319V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3'-to-5' exonuclease;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_acc=YP_009725309.1;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C18956T;aa_name=p.A6319V;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	20580	20580	.	+	.	ID=ID_28;Name=p.V6772V;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=endoRNAse;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_acc=YP_009725310.1;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G20316T;aa_name=p.V6772V;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_29;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_29;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_29;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_30;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_31;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='V70del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_32;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_31;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_31;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_30;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=0.5;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_30;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='H69del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_30;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=0.5;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21846	21846	.	+	.	ID=ID_33;Name=p.T95I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C284T;aa_name=p.T95I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21987	21987	.	+	.	ID=ID_36;Name=p.G142D;chrom_region=S;ps_filter=mask;ps_exc=amplicon_drop_or_primer_artefact,back_to_ref;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A;nt_name=c.G425A;aa_name=p.G142D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	21987	21987	.	+	.	ID=ID_36;Name=p.G142D;chrom_region=S;ps_filter=mask;ps_exc=amplicon_drop_or_primer_artefact,back_to_ref;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A;nt_name=c.G425A;aa_name=p.G142D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1;citation=Suryadevara et al. (2021);comb_mutation=;function_description=Selected twice in passage with mAb COV2-2489.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_39;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='E484K';function_description=This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_40;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='E484K', 'P681R';function_description=This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	22028	22028	.	+	.	ID=ID_41;Name=p.157del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=GAGTTCA;Variant_seq=G;nt_name=c.467_472delAGTTCA;aa_name=p.E156_R158delinsG;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=E156_R158delinsG;multiaa_comb_mutation='E156del', 'R158G';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	22028	22028	.	+	.	ID=ID_41;Name=p.R158G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=GAGTTCA;Variant_seq=G;nt_name=c.467_472delAGTTCA;aa_name=p.E156_R158delinsG;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=E156_R158delinsG;multiaa_comb_mutation='E156del', '157del';alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	22028	22028	.	+	.	ID=ID_41;Name=p.157del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=GAGTTCA;Variant_seq=G;nt_name=c.467_472delAGTTCA;aa_name=p.E156_R158delinsG;vcf_gene=S;mutation_type=;viral_lineage=AY.77;multi_aa_name=E156_R158delinsG;multiaa_comb_mutation='E156del', 'R158G';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_39;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='E484K';function_description=This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_40;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='E484K', 'P681R';function_description=This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_37;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22917	22917	.	+	.	ID=ID_38;Name=p.L452R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=G;nt_name=c.T1355G;aa_name=p.L452R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	22995	22995	.	+	.	ID=ID_42;Name=p.T478K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=A;nt_name=c.C1433A;aa_name=p.T478K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='L452R';function_description=This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='L452R', 'P681R';function_description=This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	"ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	"ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	"ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_43;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp,snp	23012	23014	.	+	.	ID=ID_44;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=A,C;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T95I';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_47;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='P681R';function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='L452R';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='L452R';function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T95I';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='L452R';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T95I';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_38;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23580	23580	.	+	.	ID=ID_48;Name=p.S673T;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=C;nt_name=c.G2018C;aa_name=p.S673T;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_47;Name=p.P681R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=G;nt_name=c.C2042G;aa_name=p.P681R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=G;nt_name=c.C2042G;aa_name=p.P681R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation='L452R', 'E484K';function_description=This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_49;Name=p.P681R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=G;nt_name=c.C2042G;aa_name=p.P681R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_49;Name=p.P681R;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=G;nt_name=c.C2042G;aa_name=p.P681R;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H];heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	24334	24334	.	+	.	ID=ID_50;Name=p.A924A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.A924A;vcf_gene=S;mutation_type=SILENT;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	25469	25469	.	+	.	ID=ID_51;Name=p.S26L;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C77T;aa_name=p.S26L;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	25658	25658	.	+	.	ID=ID_52;Name=p.T89I;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C266T;aa_name=p.T89I;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	26767	26767	.	+	.	ID=ID_53;Name=p.I82T;chrom_region=M;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=C;nt_name=c.T245C;aa_name=p.I82T;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1080/22221751.2021.1922097;citation=Shen et al. (2021);comb_mutation=;function_description=This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27346	27346	.	+	.	ID=ID_54;Name=p.Y49H;chrom_region=ORF6;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=C;nt_name=c.T145C;aa_name=p.Y49H;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27638	27638	.	+	.	ID=ID_55;Name=p.V82A;chrom_region=ORF7a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=T;Variant_seq=C;nt_name=c.T245C;aa_name=p.V82A;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27727	27727	.	+	.	ID=ID_56;Name=p.L112I;chrom_region=ORF7a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=A;nt_name=c.C334A;aa_name=p.L112I;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27752	27752	.	+	.	ID=ID_57;Name=p.T120I;chrom_region=ORF7a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C359T;aa_name=p.T120I;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27847	27847	.	+	.	ID=ID_58;Name=c.C-47T;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C-47T;aa_name=;vcf_gene=ORF8;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	27874	27874	.	+	.	ID=ID_59;Name=c.C-20T;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=C;Variant_seq=T;nt_name=c.C-20T;aa_name=;vcf_gene=ORF8;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	28027	28027	.	+	.	ID=ID_60;Name=p.W45L;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G134T;aa_name=p.W45L;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	complex,del	28247	28251	.	+	.	ID=ID_61;Name=p.L118_I121delinsFL;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=1,1;dp=2;sample_size=2;Reference_seq=AGATTTCA;Variant_seq=TC,AA;nt_name=c.AGATTTCA354_361TC;aa_name=p.L118_I121delinsFL;vcf_gene=ORF8;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	del	28270	28270	.	+	.	ID=ID_62;Name=c.-3delA;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=TA;Variant_seq=T;nt_name=c.-3delA;aa_name=;vcf_gene=N;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	28461	28461	.	+	.	ID=ID_63;Name=p.D63G;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=A;Variant_seq=G;nt_name=c.A188G;aa_name=p.D63G;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	28881	28881	.	+	.	ID=ID_64;Name=p.R203M;chrom_region=N;ps_filter=caution;ps_exc=neighbour_linked;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G608T;aa_name=p.R203M;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=RNA binding;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1;citation=Syed et al. (2021);comb_mutation=;function_description=Northern blot analysis of novel mutant virus-like-particles (VLPs) shows most increase in RNA content of any N mutation tested, suggesting that this mutation improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	28916	28916	.	+	.	ID=ID_65;Name=p.G215C;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G643T;aa_name=p.G215C;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	29402	29402	.	+	.	ID=ID_66;Name=p.D377Y;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G1129T;aa_name=p.D377Y;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	29688	29688	.	+	.	ID=ID_67;Name=c.G29688T;chrom_region=3' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=1;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G*4304T;aa_name=;vcf_gene=intergenic;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
MN908947.3	.	snp	29742	29742	.	+	.	ID=ID_68;Name=c.G29742T;chrom_region=Stem-loop,3' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=2;dp=2;sample_size=2;Reference_seq=G;Variant_seq=T;nt_name=c.G*4358T;aa_name=;vcf_gene=intergenic;mutation_type=;viral_lineage=AY.77;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Delta;status=VOC;voi_designation_date=04-Apr-2021;voc_designation_date=11-May-2021;vum_designation_date=;
